The acquired von Willebrand syndrome (AVWS) is a bleeding disorder that is frequently unrecognized or is misdiagnosed as von Willebrand disease (VWD). AVWS is characterized by structural or functional defects of von Willebrand factor (VWF) that are secondary to autoimmune, lympho-or myeloproliferative, malignant, cardiovascular or other disorders. VWF abnormalities in these disorders can result from (i) antibody-mediated clearance or functional interference, (ii) adsorption to surfaces of transformed cells or platelets, or (iii) increased shear stress and subsequent proteolysis. Diagnosis can be challenging as no single test is usually sufficient to prove or exclude AVWS. Furthermore, there are no evidence-based guidelines for management. Treatments of the underlying medical condition, including chemo/radiotherapy, surgery, immunosuppressants, plasmapheresis or immunoadsorption, can result in remission of AVWS, but is not always feasible and successful. Due to the heterogeneous mechanisms of AVWS, more than one therapeutic approach is often required to treat acute bleeds and for prophylaxis during invasive procedures; the treatment options include, but are not limited to, desmopressin, VWF-containing concentrates, intravenous immunoglobulin, or recombinant factor VIIa. Here we review the management of AVWS with an overview on the currently available evidence and additional considerations for typical treatment situations.
Introduction
Managing the acquired von Willebrand syndrome (AVWS) remains a difficult task for the practicing hematologist, despite several reviews published on the pathology, diagnosis and management of this disorder. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Most reviews have concluded that AVWS is underdiagnosed and sometimes misdiagnosed, probably because of the broad spectrum of its clinical and laboratory features. Recent data suggest that AVWS is becoming more prevalent and that general hematologists are more likely to be referred patients with this condition. Following a brief overview of its epidemiology and pathophysiology, we focus on the practical diagnosis and management of AVWS.
Definition. In contrast to inherited von Willebrand disease (VWD), the diagnostic category of AVWS includes any qualitative, structural or functional disorder of von Willebrand factor (VWF) that is not inherited and is associated with an increased risk of bleeding. Therefore, a key aspect of the diagnostic workup is the exclusion of a bleeding history in other family members.
Epidemiology. The true prevalence of AVWS has not yet been established. Only 266 cases were reported in the literature from its first description in 1968 15 until 1999. An additional 186 cases were reported in the International Society on Thrombosis and Haemostasis (ISTH) registry, a retrospective survey published in 2000. 16 Budde et al. reported 187 cases diagnosed in a German reference laboratory among 5,014 plasma samples from patients with bleeding disorders received over a 2-year period. 17 Based on these figures, AVWS appears to be a relatively uncommon disorder.
AVWS is usually associated with an underlying disorder. According to the ISTH registry, lymphoproliferative (48%), cardiovascular (21%), myeloproliferative (15%), other neoplastic (5%) and autoimmune disorders (2%) are most frequent. 16 Less commonly, AVWS has been described in hypothyroidism, uremia, or without an underlying disorder. In recent cohort studies, an increased association with cardiovascular disorders (40-46%) was found, possibly reflecting higher awareness among cardiologists and cardiac surgeons ( Figure 1 ). 17, 18 More recently, AVWS has been frequently diagnosed in selected cohorts of patients with aortic valve stenosis (79%) 19 
and continuous-flow left ventricular assist devices (LVAD, up to
For personal use only. on September 14, 2017 . by guest www.bloodjournal.org From 100%). [20] [21] [22] The latter have received increased attention of late because of the increasing numbers of heart failure patients who are being maintained for prolonged periods while awaiting transplant, and because of the increased recognition of chronic gastrointestinal bleeds from intestinal arterio-venous malformations in this setting. These data suggest that AVWS is becoming more prevalent than previously assumed, at least in certain groups of patients.
According to the age distribution of underlying disorders, AVWS occurs in every age group, but is most frequent in the elderly with a median age of 62 (range 2-96) at the time of diagnosis. Pathogenesis. In contrast to acquired hemophilia, which is attributable to neutralizing autoantibodies against factor VIII (FVIII), a variety of pathogenic mechanisms have been proposed to cause structural or functional disturbances of VWF. These include autoantibodies, either interfering with platelet [23] [24] [25] [26] [27] [28] or collagen binding, [29] [30] [31] or increasing VWF clearance from the plasma. 32 Sequestration of high-molecular weight (HMW) multimers was demonstrated in patients with hematological disorders due to adsorption to myeloma cells or platelets, but also in reactive thrombocytosis. [33] [34] [35] [36] Proteolytic cleavage of VWF can occur after shear stress-induced unfolding, 37,38 and AVWS due to this mechanism was described in disorders with increased shear stress, in particular aortic valve stenosis 19, 37, 39 and LVAD. [20] [21] [22] Proteolytic cleavage has also been described in patients with pancreatitis, liver cirrhosis, leukemia and certain medications. 40, 41 In hypothyroidism, AVWS seems to result from decreased synthesis of otherwise normal VWF.
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Paths to diagnosis
There are two main scenarios in which the diagnosis of AVWS should be considered: (i) bleeding patients in whom laboratory testing suggests abnormalities of VWF, and (ii) patients with known AVWS-associated disorders seeking advice before undergoing procedures associated with a high risk of bleeding ( Figure 2 ).
When should we consider the diagnosis of AVWS in a bleeding patient? VWD is considered to be the most frequent hereditary bleeding disorder, 43 and must be considered in the differential diagnosis of every new bleeding patient who does not have another obvious etiology. Initial laboratory findings typical of VWD do generally not allow differentiation between VWD and
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From AVWS. Therefore, AVWS must be considered whenever laboratory findings would suggest VWD, in particular in the presence of AVWS-associated disorders (Figure 2A ). Even if an AVWS-associated disorder is not known, attention must be paid because the disorder may not have been previously identified.
How to differentiate AVWS from VWD? Distinguishing AVWS and VWD is important because the approaches to treatment can be very different. Points to consider in the differential diagnosis are summarized in Table 1 . In most cases the differentiation is straightforward, although there is no single aspect sufficient on its own. Late onset of bleeding and negative family history should prompt the suspicion of AVWS, but additional workup can be required since mild VWD can be asymptomatic for decades and lack a remarkable family history due to its low penetrance. On the other hand, the presence of an AVWS-associated disorder does not prove AVWS since these disorders could be present coincidentally. In uncertain cases, testing of family members, genetic analysis, and assays for VWF-specific antibodies and inhibitors can be helpful.
Should we actively search for AVWS-associated disorders?
We recommend screening for AVWS-associated disorders in all patients with laboratory findings typical of VWD and a negative family history. Careful history taking and physical examination should be sufficient to rule out most AVWS-associated cardiovascular disorders, in particular severe aortic valve stenosis. Likewise, most hematological, malignant and autoimmune disorders should be addressed clinically. In addition, serum protein electrophoresis and a complete blood count should be obtained to screen for monoclonal gammopathy and other hematological disorders, respectively.
Should we consider AVWS in non-bleeding patients with AVWS-associated disorders?
A patient with AVWS may have a negative bleeding history simply because the condition has not existed long enough to become symptomatic. In our own practices, we offer testing to patients with AVWS-associated disorders prior to major surgery and other interventions with a high risk of bleeding ( Figure 2B ). Although this is in line with a recommendation by the ISTH, 16 the value of testing and treating AVWS in previously asymptomatic patients has not been evaluated by clinical trials. Since AVWS-associated disorders are relatively common in the population, it remains possible that testing might produce many false-positive results and result in unnecessary treatments. Therefore, diagnostic testing in asymptomatic patients should be based 
Diagnostic tests
Routine tests. The initial tests used to assess AVWS are the same as for VWD. Figure 3 Figure   4 . A loss or decrease of HMW multimers can be quantified using densitometry. 44 
General treatment options
The treatment goals in AVWS are: (1) to control acute bleeds, (2) to prevent bleeding in highrisk situations, and (3) to obtain long-term remission. The strategies utilized to obtain these goals depend on the underlying disease mechanisms (Table 2) . Whenever possible, treatment should address the underlying disorder, thereby aiming to treat AVWS as well. Unfortunately, treatment of the underlying disorder is not always possible, and obtaining partial remission of the underlying disorder does not always result in an improvement of the bleeding symptoms typical of AVWS. Therefore, additional treatments as listed in Table 2 are usually required to control or to prevent bleeding. The available evidence for efficacy and safety of the commonly used haemostatic treatments is summarized below.
Desmopressin. This synthetic analogue of vasopressin can be used to prevent and control bleeding in some patients with AVWS. It is usually administered in doses of 0.3 µg/kg over 30
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However, success rates varied according to the underlying disorder: they were low in cardiovascular (10%) and myeloproliferative (21%), but higher in autoimmune (33%), lymphoproliferative (44%) and other neoplastic disorders (75%). 16 In the only prospective clinical trial, performed in 10 patients with MGUS, all VWF measurements improved after 30
min, but returned close to baseline after 4 hours. 49 We therefore closely monitor VWF:Ag and VWF:RCo, when desmopressin is used for prophylaxis and treatment of bleeds. Caution must be exercised in patients with cardiovascular disorders and in the elderly to prevent fluid overload and hyponatremia, which are the most common adverse effects of desmopressin.
VWF-containing concentrates. Several plasma-derived concentrates containing VWF can be used for replacement therapy. In our practice, we use starting doses between 30 and 100 VWF:RCo units/kg depending on the patient's residual activity, severity of bleeding and presence of inhibitors. Similar to desmopressin, the half-life of infused VWF can be very short, in particular in patients with MGUS or inhibitors. 49 Close monitoring of the clinical response and VWF measurements are needed for tailoring doses and dosing intervals.
Recombinant factor VIIa (rFVIIa). Use of this hemostatic agent has been reported in AVWS
and in VWD patients, particularly those who develop alloantibodies against VWF. It is usually administered with a dose of 90 µg/kg (range 40-150) and for a median of 3 doses (range 1-54).
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Treatment is usually effective with responses reported in 96% of patients. Adverse events appear to be uncommon; myocardial infarction was reported in one patient with type 2A
VWD. 51 The rate of thromboembolic complications is low in hemophilia patients receiving rFVIIa, but it is currently unknown whether this is holds for patients with AVWS or VWD.
Caution should be exerted, particularly in elderly patients and those at risk of thromboembolism.
Antifibrinolytics. The currently available antifibrinolytic drugs are the lysine analogues hours), and 4-aminomethylbenzoic acid (50-100 mg every 6 to 8 hours). These drugs can be administered orally, intravenously or topically. They bind to plasminogen and plasmin, thereby inhibiting binding to fibrin. Antifibrinolytics increase clot strength in some in vitro models of hemostasis. 52 They are primarily used as adjunct therapies together with desmopressin or VWFcontaining concentrates for surgery and bleeding in areas of high fibrinolytic activity, i.e. the gastrointestinal and urogenital tracts. For minor bleeds in these areas, treatment with
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Intravenous immunoglobulin (IVIG).
The effectiveness of IVIG was demonstrated in an openlabel cross-over study in patients with AVWS associated with MGUS of the IgG class (IgG-MGUS). Doses of 1 g/kg per day were used for 2 days. 49 An increase of VWF measurements and shortening of the bleeding time were observed on the day after the second infusion, reaching a maximum after 4 days and slowly returning to baseline within 21 days. IVIG was not effective in AVWS patients with MGUS of the IgM class (IgM-MGUS).
Plasmapheresis. Plasmapheresis can be used to deplete autoantibodies and paraproteins of any immunoglobulin class and has been reported in patients with AVWS due to IgM-MGUS. 5 Fresh frozen plasma should be used, instead of albumin, to prevent depletion of fibrinogen and other coagulation factors, which might provoke bleeding in patients with AVWS. In case of severe bleeding, restoration of VWF can be accelerated by the concurrent replacement with VWFcontaining concentrate or desmopressin.
Specific approaches according to underlying disorders Lymphoproliferative and autoimmune disorders
Lymphoproliferative disorders account for a significant proportion of cases with AVWS, both in the literature (30%) and in the ISTH registry (48%). 16 Other 49 Plasmapheresis combined with VWF-containing concentrates has been reported to be effective. 54 In addition, antifibrinolytics can be helpful, particularly for mucocutaneous bleeds.
How to induce long-term remission?
Treatment of the underlying disorder should be considered whenever possible. MGUS usually remains untreated in asymptomatic patients. If it becomes symptomatic due to AVWS, an effective long-term therapy would be highly warranted, but unfortunately has not been established. Chemotherapy and steroids are usually ineffective, apparently because these drugs cannot eradicate slowly proliferating plasma cell clones. Rituximab has also been used without success in one reported case. 55 Another case report suggests that the proteasome inhibitor bortezomib could be effective. 56 
Cardiovascular disorders
AVWS associated with cardiovascular disorders is increasingly recognized. Publications in the field have mainly focused on aortic valve stenosis and more recently on LVAD, but it should be noted that a broad range of congenital and acquired cardiac defects have been reported in association with AVWS, including dysfunctional valve prostheses, endocarditis, septal defects and others. [16] [17] [18] For even increased. [16] [17] [18] [19] [20] [21] [22] The VWF:RCo/Ag and VWF:CB/Ag ratio is often but not always reduced. 16, 18, 19, 22 In some patients a loss or decrease of HMW multimers is the only laboratory abnormality indicating AVWS. It is not generally accepted that reduced HMW multimers alone, without a disproportional decrease of VWF:RCo or VWF:CB, can explain bleeding. On the other hand, a striking incidence of hemorrhage was reported in patients with severe aortic valve stenosis (21% during 6 months before surgery) 19 and LVAD (31% during a median follow-up of 28 months). 22 Virtually all of these patients exhibit a decrease of HMW multimers, but only 44 to 79% of them have a reduced VWF:CB/Ag ratio. 18, 19, 22 Moreover, the frequency of bleeding is not related to the level of VWF:Ag or VWF:RCo. 21 For these reasons, we currently consider a lack of HWM multimers alone to be a risk factor for bleeding, but further studies are needed to provide direct evidence.
What are the preferred treatment modalities? Treatment should aim to correct the cardiac defect whenever possible. Removal of LVAD has been reported to result in a remission of AVWS. 22 Likewise, valve replacement for aortic valve stenosis usually results in an improvement of AVWS, although recurrence was noted in some patients, in particular those with prosthesis malfunction. 19 In some patients frequent and severe bleeding due to AVWS may even be considered a sufficient indication for surgical correction even if the cardiac defect would not require surgery on its own. The risk of future bleeds and the potential benefit of correction must, however, be carefully weighed against the risks of the procedure.
Other treatment modalities are limited and based on anecdotal evidence. Antifibrinolytics may be considered, in particular for mucocutaneous bleeding, although the thromboembolic risk remains a concern in high-risk patients. 58 Desmopressin has not been very successful in this setting, with response rates of 10%. 16 Moreover, we do not use this agent in patients with congestive heart failure, coronary artery disease or advanced age (≥65 years 47 It therefore appears likely that additional risk factors such as platelet function defects contribute to bleeding. The relationship between platelet count, AVWS, platelet function defects and the risk of bleeding deserves further study. For the time being, we suggest that bleeding patients with MPN be screened for both AVWS and platelet function defects.
What determines the risk of thrombosis?
Thrombosis is a challenging problem because bleeding patients with MPN are also at increased risk for thrombosis, which might be further increased by measures to improve hemostasis. In fact the overall frequency of thrombosis in MPN (6.6 per 100 patient-years) appears to be higher than the risk of major bleeding (0.33 per 100 patient-years). 65 Thrombotic events are more often arterial than venous. Known risk factors are advanced age (≥60 years) and previous thromboembolic events. 65, 66 Leukocytosis, 67 increased marrow fibrosis, 68 and the JAK2 V617F mutation 69 have also been reported as risk factors in ET. An association between the platelet count and the risk of thrombosis is not well established. Cytoreductive therapy consistently lowered the risk of thrombosis in several clinical trials. In ET patients on hydroxyurea, the remaining risk of thrombosis was associated with age, previous thrombosis and leukocytosis (>10 /nl), but not with the platelet count.
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How to treat bleeding patients with MPN? Cytoreductive therapy was reported to result in remission of AVWS in 12 of 14 patients with MPN and should be considered in bleeding patients. 47 Usually, treatment is not immediately effective and additional treatments can be required in actively bleeding patients. In theory, desmopressin should be a preferred treatment because newly released VWF from endothelial cells contains very large HMW multimers, larger than those contained in plasma-based concentrates. However, desmopressin can fail in situations of acute bleeding because of tachyphylaxis or if endothelial storage pools have already been mobilized by different mechanisms. The reported success rate in patients with MPN has been 21%. 16 VWF-containing concentrates have not been reported to result in higher success rates. 16 However, in our experience higher doses (e.g. 50 IU/kg two or three times daily) sometimes result in better treatment results. Alternatively, rFVIIa may be considered for severe bleeding refractory to other treatment modalities.
How to address thrombotic risks in these patients? There is a consensus that cardiovascular risk factors should be addressed. Statins have also been recommended. 71 Primary prophylaxis with aspirin is generally recommended in PV and ET unless contraindicated. The main contraindications are intolerance and bleeding. Known AVWS in non-bleeding patients can be
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If thromboembolic events occur in patients with asymptomatic AVWS, we usually administer antithrombotic drugs in the same way as in the general population. This includes antiplatelet drugs for arterial events and anticoagulants for venous events. In case of concurrent bleeding and thrombosis, the choice of drugs and dosing always is an individual decision. We try to avoid potentially thrombogenic medications, and provide as much antithrombotic therapy as needed and tolerated. For deep vein thrombosis, compression therapy is important. In case of clinically significant pulmonary embolism, temporary inferior vena cava filters can be considered.
Conclusion
AVWS is a significant under-recognized bleeding disorder occurring in several different clinical situations. The diagnostic approach to AVWS remains a challenge to the practicing physician due to the variable clinical presentation and the many different tests that have to be obtained to prove or rule out the diagnosis. Management requires consideration of the underlying disorder and pathogenic mechanisms. We have reviewed here the relatively limited evidence that is available from registries, cohort studies and a few clinical trials, and also shared our personal experience on how to manage difficult situations. Research in this area has been limited by a number of difficulties, including the prolonged follow up required, the many confounding factors and increasingly documented clinical and biological heterogeneity. Since prospective clinical studies are difficult to organize in this small and heterogeneous group of patients, we encourage physicians to report their experience in the ongoing AVWS registry commenced by the ISTH (www.IntReAVWS.com).
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